Biovest International, Inc. Study Backs Non-Hodgkin’s Lymphoma Anti-Cancer Vaccine

Tampa Bay Business Journal -- Biovest International Inc. said a Phase III clinical study has shown that BiovaxID significantly prolonged disease-free survival in follicular non-Hodgkin’s lymphoma.
MORE ON THIS TOPIC